Teva Pharmaceutical Industries Limited

Yeda Research and Develpment & Co. Ltd

Technion Research & Development Foundation Ltd

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Adrian Gilbert

Daniella Licht

Sharon Cohen-Vered

Milka Linenberg

Shulamit Patashnik

Ruth Arnon

Michael Sela

Dvora Teitelbaum

Ety Klinger

Ioana Lovinger

Vera Weinstein

Esmira Naftali

Rivka Riven-Kreitman

Fanny Caciularu

Ramon F Joubran

Rivka Riven-Kreitmann

Sharon Cohen-vered

Shulami Patashnik

The invention relates to a pharmaceutical composition comprising a pharmaceutically acceptable salt of N-ethyl-N-phenyl-1,2,-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, N-methylglucamine, and a pharmaceutically acceptable carrier.

Stable laquinimod preparations

Disclosed are formulations of ladostigil tartrate, including pharmaceutical compositions, process for the manufacture, and use thereof.

Formulations of ladostigil tartrate

The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-;and a substituted &#x3b2;-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition has a pH between 4 and 9, a process for preparation, and a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition.

Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus

Pharmaceutical compositions useful for treating autoimmune diseases in a mammal comprising as an active ingredient a therapeutically effective amount of Copolymer 1, and microcrystalline cellulose are disclosed. Processes for the manufacture of such compositions are also disclosed.

Oral, nasal and pulmonary dosage formulations of copolymer 1

The present invention relates to the treatment of multiple sclerosis by ingestion or inhalation of copolymet-1 and pharmaceutical compositions useful for such treatment.

Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1

Growing community of inventors

Rananna, Israel

Adrian Gilbert